Black Diamond Therapeutics, Inc. (BDTX): Total Liabilities
$30.80M
As of 2025-12-31
$28.94M
As of 2026-06-30
-8.8%
3-year compound annual growth
+7.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.80M | -21.7% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $39.35M | -5.9% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $41.83M | +3.1% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $40.56M | -21.7% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $51.78M | +136.3% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $21.91M | +349.1% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $4.88M | -26.1% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $6.60M | n/a | 2020-03-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $30.80M | -21.7% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $237.55M | -4.4% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $343.26M | -17.0% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $410.94M | +15.6% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $61.05M | +22.6% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $35.34M | -43.0% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $34.12M | +12.9% |
Compare BDTX, VIR, RXRX, AUTL side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗